In September 2026, DSK Medical Technology (Hong Kong) Limited officially launched its medical device regulatory and cross-border market access advisory practice, supporting medical device and life-science companies that plan to enter the Hong Kong market — or use Hong Kong as a gateway to international markets.

The launch responds to a structural shift in the regulatory landscape. Hong Kong's Medical Device Administrative Control System (MDACS) is moving from voluntary participation to mandatory regulation: from March 2026, medical devices procured by the Department of Health must be listed; under the published timetable, all importers and distributors will be required to register from 2027. Meanwhile, the Centre for Medical Products Regulation (CMPR) will be established by the end of 2026, and the HKSAR First Five-Year Plan (2026–2030) explicitly calls for accelerating medical innovation and industrial chain development. Rules are tightening while pathways are opening — the point at which professional advisory value is most concentrated.

First, how to bring a product to market in Hong Kong compliantly. The firm provides end-to-end support for MDACS listing — device classification assessment, evaluation and selection between the two application pathways (reference jurisdiction marketing approval, or conformity assessment via a Certified Assessment Body), dossier preparation and submission, and progress tracking. It also acts as Local Responsible Person (LRP) carrying statutory duties under the Code of Practice for LRPs (COP-01), including post-market obligations: adverse event monitoring and reporting, vigilance record management, long-term documentation retention, recall coordination, and day-to-day liaison with the Department of Health.

Second, how to move products across borders. For mainland Chinese companies, the firm advises on structuring Hong Kong as a first stop for international entry, feasibility assessment for the Greater Bay Area "Yaoxietong" (Hong Kong-Macao medicine and device connect) scheme, Southeast Asia and Middle East market entry structured from Hong Kong, and compliant design of cross-border trading arrangements. For international brands, it advises on NMPA import registration strategy, domestic responsible person arrangements, and distribution architecture — with on-the-ground execution supported by Shenzhen DSK Dental Equipment Co., Ltd., which brings over a decade of distribution and hospital tendering experience in the Chinese market.

Third, how to connect clinical trial resources. As Hong Kong accelerates its development as an international clinical trial hub — including the newly announced International Academy of Clinical Trials — cross-border trial resources are converging. The firm advises on trial pathway design (dual-region multi-site layout), ethics submission and site selection advisory, liaison with Hong Kong's clinical ecosystem (hospitals, CROs, academic centres), and tracking of real-world data applications.

The firm's judgement is built on more than a decade of industry practice. Its affiliate, Shenzhen DSK Dental Equipment Co., Ltd. (founded 2015), has worked in dental medical device distribution, maintaining long-term partnerships with more than twenty international brands, serving over one hundred and fifty hospital projects, and participating regularly in public hospital tendering. The team understands both manufacturers' compliance needs and how end-market channels actually operate.

The Hong Kong entity takes the other side of the equation — rules. Based in Hong Kong, it focuses on regulatory research, cross-border access, and compliant structure design. Products and channels in Shenzhen; rules and access in Hong Kong. Clients gain a complete chain from pathway planning through to channel execution, rather than an advisory report that stops at the paper stage.

The practice also aligns with the HKSAR First Five-Year Plan (2026–2030) on medical innovation and industrial chain development, and with the Northern Metropolis life & health corridor. In a cycle where policy resources are converging on healthcare, translating policy language into executable market access pathways is the role this practice intends to hold for the long term.